ESR1 and osteoporosis: This is supported by successful clinical application of synthetic estrogen receptor α (ERα: ERS1) ligands, called selective estrogen receptor modulators (SERMs), as anti-osteoporosis drugs with reduced estrogenic adverse effects [18,19].